Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of XXXX ?

@entity1 @entity66 @entity134 @entity292 @entity30
The high cost of infliximab inhibits the regular retreatment of all @entity1 in Hungary with @entity30 ( @entity30 ) after beneficial induction therapy. This study is set out to evaluate the medium-term efficacy of induction therapy with infliximab without retreatment in @entity30 @entity1 with chronic activity and/or fistulae refractory to conventional therapy. METHODS: A retrospective 1-year review was undertaken of all @entity30 @entity1 with successfully induced remission or @entity292 closure with 3 infusions of infliximab. Infliximab was administered in a dose of 5  mg/kg 3 times, in weeks 0, 2 and 6. Clinical remission was defined as symptom resolution and an estimated @entity30 Activity Index (CDAI) <150 and complete @entity292 closure. We evaluated the clinical response, the estimated CDAI, the number of draining fistulae, the dosages of @entity134 and immunosuppressive drugs at 6 and 12  months after the last infusion, and the needs for hospitalization and surgical intervention during this period. Breslow (Generalized Wilcoxon) test was used as the statistical method. RESULTS: The data of the 50 @entity1 (19 luminal, 31 fistulizing disease; average age 29. 3 [13-59] years, disease localization: 23 colon, 13 ileum, 13 ileocolon, 1 duodenum) were suitable for analysis. Infliximab induction therapy without retreatment resulted in a beneficial effect lasting for at least 1  year in 22 of the 50 @entity1 (44%). 11 of the 19 @entity1 (57.9%) with @entity66 remained in steroid-free complete remission, while the fistulae persisted closed in only 11 of the 31 @entity1 (35.5%) (p<0.05). CONCLUSION: Infliximab induction therapy alone may result in sustained remission mainly in @entity1 with @entity66 . These results suggest the need for maintenance therapy with infliximab after successful therapy induction in @entity1 with fistulae, while luminal @entity30 @entity1 could possibly participate in regular retreatment only if needed. If these data are confirmed, this modification of the therapeutic procedure could well increase the cost-effectiveness of infliximab.
